{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T12:00:38Z","timestamp":1794657638956,"version":"4.9.1"},"reference-count":87,"publisher":"Springer Science and Business Media LLC","issue":"8067","license":[{"start":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T00:00:00Z","timestamp":1745971200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T00:00:00Z","timestamp":1745971200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nature"],"published-print":{"date-parts":[[2025,6,12]]},"DOI":"10.1038\/s41586-025-08940-0","type":"journal-article","created":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T07:07:12Z","timestamp":1746169632000},"page":"458-466","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":530,"title":["Global evolution of inflammatory bowel disease across epidemiologic stages"],"prefix":"10.1038","volume":"642","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8618-7544","authenticated-orcid":false,"given":"Lindsay","family":"Hracs","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7539-9103","authenticated-orcid":false,"given":"Joseph W.","family":"Windsor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Gorospe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Cummings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0675-7226","authenticated-orcid":false,"given":"Stephanie","family":"Coward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2909-9721","authenticated-orcid":false,"given":"Michael J.","family":"Buie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-8186-8827","authenticated-orcid":false,"given":"Joshua","family":"Quan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quinn","family":"Goddard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7973-5995","authenticated-orcid":false,"given":"L\u00e9a","family":"Caplan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-0212-0540","authenticated-orcid":false,"given":"Ante","family":"Markovinovi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5029-2345","authenticated-orcid":false,"given":"Tyler","family":"Williamson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-1383-519X","authenticated-orcid":false,"given":"Yvonne","family":"Abbey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murdani","family":"Abdullah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria T.","family":"Abreu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vineet","family":"Ahuja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raja Affendi","family":"Raja Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7200-0702","authenticated-orcid":false,"given":"Mansour","family":"Altuwaijri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9598-2577","authenticated-orcid":false,"given":"Domingo","family":"Balderramo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rupa","family":"Banerjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8855-3598","authenticated-orcid":false,"given":"Eric I.","family":"Benchimol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8041-3574","authenticated-orcid":false,"given":"Charles N.","family":"Bernstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8661-0608","authenticated-orcid":false,"given":"Eduard","family":"Brunet-Mas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3312-5139","authenticated-orcid":false,"given":"Johan","family":"Burisch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vui Heng","family":"Chong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris","family":"Dotan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Usha","family":"Dutta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6153-1081","authenticated-orcid":false,"given":"Sara","family":"El Ouali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0186-5877","authenticated-orcid":false,"given":"Angela","family":"Forbes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1906-4982","authenticated-orcid":false,"given":"Anders","family":"Forss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Gearry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3685-9496","authenticated-orcid":false,"given":"Viet Hang","family":"Dao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juanda Leo","family":"Hartono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ida","family":"Hilmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7231-0804","authenticated-orcid":false,"given":"Phoebe","family":"Hodges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7355-2357","authenticated-orcid":false,"given":"Gareth-Rhys","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8610-9925","authenticated-orcid":false,"given":"Fabi\u00e1n","family":"Juliao-Ba\u00f1os","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0783-4441","authenticated-orcid":false,"given":"Jamilya","family":"Kaibullayeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0844-6448","authenticated-orcid":false,"given":"Paul","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2073-4234","authenticated-orcid":false,"given":"Taku","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9632-6691","authenticated-orcid":false,"given":"Paulo Gustavo","family":"Kotze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3948-6488","authenticated-orcid":false,"given":"Peter L.","family":"Lakatos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlie W.","family":"Lees","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5867-0312","authenticated-orcid":false,"given":"Julajak","family":"Limsrivilai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0252-9341","authenticated-orcid":false,"given":"Bobby","family":"Lo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7199-6851","authenticated-orcid":false,"suffix":"Jr","given":"Edward V.","family":"Loftus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1024-5602","authenticated-orcid":false,"given":"Jonas F.","family":"Ludvigsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5221-7349","authenticated-orcid":false,"given":"Joyce W. Y.","family":"Mak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8193-5198","authenticated-orcid":false,"given":"YingLei","family":"Miao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9156-2903","authenticated-orcid":false,"given":"Ka Kei","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2683-9018","authenticated-orcid":false,"given":"Shinji","family":"Okabayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5478-7019","authenticated-orcid":false,"given":"Ola","family":"Ol\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5247-940X","authenticated-orcid":false,"given":"Remo","family":"Panaccione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2727-4688","authenticated-orcid":false,"given":"Mukesh Sharma","family":"Paudel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3985-7402","authenticated-orcid":false,"given":"Abel Botelho","family":"Quaresma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5647-1723","authenticated-orcid":false,"given":"David T.","family":"Rubin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1131-5836","authenticated-orcid":false,"given":"Marcellus","family":"Simadibrata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8994-6163","authenticated-orcid":false,"given":"Hidekazu","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Toro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5160-868X","authenticated-orcid":false,"given":"Dan","family":"Turner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Iade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5017-5840","authenticated-orcid":false,"given":"Shu Chen","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5247-5812","authenticated-orcid":false,"given":"Jesus K.","family":"Yamamoto-Furusho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2772-2575","authenticated-orcid":false,"given":"Suk-Kyun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6850-4454","authenticated-orcid":false,"given":"Siew C.","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2719-0556","authenticated-orcid":false,"given":"Gilaad G.","family":"Kaplan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Global IBD Visualization of Epidemiology Studies in the 21st Century (GIVES-21) Research Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,30]]},"reference":[{"key":"8940_CR1","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1038\/nrgastro.2015.150","volume":"12","author":"GG Kaplan","year":"2015","unstructured":"Kaplan, G. G. The global burden of IBD: from 2015 to 2025. Nat. Rev. Gastroenterol. Hepatol. 12, 720\u2013727 (2015).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"8940_CR2","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/s41575-020-00360-x","volume":"18","author":"GG Kaplan","year":"2021","unstructured":"Kaplan, G. G. & Windsor, J. W. The four epidemiological stages in the global evolution of inflammatory bowel disease. Nat. Rev. Gastroenterol. Hepatol. 18, 56\u201366 (2021).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"8940_CR3","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1053\/j.gastro.2011.10.001","volume":"142","author":"NA Molodecky","year":"2012","unstructured":"Molodecky, N. A. et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 142, 46\u201354 (2012).","journal-title":"Gastroenterology"},{"key":"8940_CR4","doi-asserted-by":"publisher","first-page":"2769","DOI":"10.1016\/S0140-6736(17)32448-0","volume":"390","author":"SC Ng","year":"2017","unstructured":"Ng, S. C. et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet 390, 2769\u20132778 (2017).","journal-title":"Lancet"},{"key":"8940_CR5","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/S2468-1253(16)30077-2","volume":"1","author":"GG Kaplan","year":"2016","unstructured":"Kaplan, G. G. & Ng, S. C. Globalisation of inflammatory bowel disease: perspectives from the evolution of inflammatory bowel disease in the UK and China. Lancet Gastroenterol. Hepatol. 1, 307\u2013316 (2016).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"8940_CR6","unstructured":"Xue, M. et al. Environmental factors associated with risk of Crohn\u2019s disease development in the Crohn\u2019s and Colitis Canada\u2014Genetic, Environmental, Microbial Project. Clin. Gastroenterol. Hepatol. 22, 1889\u20131897 (2024)."},{"key":"8940_CR7","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1053\/j.gastro.2016.10.020","volume":"152","author":"GG Kaplan","year":"2017","unstructured":"Kaplan, G. G. & Ng, S. C. Understanding and preventing the global increase of inflammatory bowel disease. Gastroenterology 152, 313\u2013321 (2017).","journal-title":"Gastroenterology"},{"key":"8940_CR8","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1053\/j.gastro.2021.12.282","volume":"162","author":"ME Kuenzig","year":"2022","unstructured":"Kuenzig, M. E. et al. Twenty-first century trends in the global epidemiology of pediatric-onset inflammatory bowel disease: systematic review. Gastroenterology 162, 1147\u20131159 (2022).","journal-title":"Gastroenterology"},{"key":"8940_CR9","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.crohns.2013.09.009","volume":"8","author":"DJ Mulder","year":"2014","unstructured":"Mulder, D. J., Noble, A. J., Justinich, C. J. & Duffin, J. M. A tale of two diseases: the history of inflammatory bowel disease. J. Crohns Colitis 8, 341\u2013348 (2014).","journal-title":"J. Crohns Colitis"},{"key":"8940_CR10","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1111\/j.1365-2036.2007.03576.x","volume":"27","author":"S Gunesh","year":"2008","unstructured":"Gunesh, S., Thomas, G. A., Williams, G. T., Roberts, A. & Hawthorne, A. B. The incidence of Crohn\u2019s disease in Cardiff over the last 75 years: an update for 1996-2005. Aliment Pharmacol. Ther. 27, 211\u2013219 (2008).","journal-title":"Aliment Pharmacol. Ther."},{"key":"8940_CR11","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1016\/j.crohns.2014.06.004","volume":"8","author":"Z Vegh","year":"2014","unstructured":"Vegh, Z. et al. Incidence and initial disease course of inflammatory bowel diseases in 2011 in Europe and Australia: results of the 2011 ECCO-EpiCom inception cohort. J. Crohns Colitis 8, 1506\u20131515 (2014).","journal-title":"J. Crohns Colitis"},{"key":"8940_CR12","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1053\/j.gastro.2023.07.003","volume":"165","author":"JD Lewis","year":"2023","unstructured":"Lewis, J. D. et al. Incidence, prevalence, and racial and ethnic distribution of inflammatory bowel disease in the United States. Gastroenterology 165, 1197\u20131205 (2023).","journal-title":"Gastroenterology"},{"key":"8940_CR13","doi-asserted-by":"crossref","unstructured":"Jones, G. R. et al. IBD prevalence in Lothian, Scotland, derived by capture-recapture methodology. Gut 68, 1953\u20131960 (2019).","DOI":"10.1136\/gutjnl-2019-318936"},{"key":"8940_CR14","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1053\/j.gastro.2019.01.002","volume":"156","author":"S Coward","year":"2019","unstructured":"Coward, S. et al. Past and future burden of inflammatory bowel diseases based on modeling of population-based data. Gastroenterology 156, 1345\u20131353 (2019).","journal-title":"Gastroenterology"},{"key":"8940_CR15","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.14309\/ajg.0000000000002687","volume":"119","author":"S Coward","year":"2024","unstructured":"Coward, S. et al. Forecasting the incidence and prevalence of inflammatory bowel disease: a Canadian nationwide analysis. Am. J. Gastroenterol. 119, 1563\u20131570 (2024).","journal-title":"Am. J. Gastroenterol."},{"key":"8940_CR16","first-page":"100298","volume":"13","author":"AB Quaresma","year":"2022","unstructured":"Quaresma, A. B. et al. Temporal trends in the epidemiology of inflammatory bowel diseases in the public healthcare system in Brazil: a large population-based study. Lancet Reg. Health Am. 13, 100298 (2022).","journal-title":"Lancet Reg. Health Am."},{"key":"8940_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10115-007-0114-2","volume":"14","author":"X Wu","year":"2008","unstructured":"Wu, X. et al. Top 10 algorithms in data mining. Knowl. Inform. Syst. 14, 1\u201337 (2008).","journal-title":"Knowl. Inform. Syst."},{"key":"8940_CR18","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1023\/A:1010933404324","volume":"45","author":"L Breiman","year":"2001","unstructured":"Breiman, L. Random forests. Mach. Learn. 45, 5\u201332 (2001).","journal-title":"Mach. Learn."},{"key":"8940_CR19","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/S2468-1253(23)00003-1","volume":"8","author":"J Burisch","year":"2023","unstructured":"Burisch, J. et al. The cost of inflammatory bowel disease in high-income settings: a Lancet Gastroenterology & Hepatology Commission. Lancet Gastroenterol. Hepatol. 8, 458\u2013492 (2023).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"8940_CR20","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1111\/ehr.13064","volume":"74","author":"L Prados de la Escosura","year":"2021","unstructured":"Prados de la Escosura, L. Augmented human development in the age of globalization. Econ. Hist. Rev. 74, 946\u2013975 (2021).","journal-title":"Econ. Hist. Rev."},{"key":"8940_CR21","unstructured":"Global Health Observatory. Prevalence of Obesity Among Adults, BMI\u226530, Age-Standardized Estimates by Country (World Health Organization, 2017); apps.who.int\/gho\/data\/node.main.A900A?lang=en."},{"key":"8940_CR22","unstructured":"Department of Economic and Social Affairs-Population Division. World Urbanization Prospects: The 2018 Revision (United Nations, 2018); population.un.org\/wup\/Download\/."},{"key":"8940_CR23","unstructured":"Tracking Universal Health Coverage: 2023 Global Monitoring Report (World Health Organization and International Bank for Reconstruction and Development\/The World Bank, 2023)."},{"key":"8940_CR24","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1017\/S136898002000350X","volume":"24","author":"A Azzam","year":"2021","unstructured":"Azzam, A. Is the world converging to a \u2018Western diet\u2019? Publ. Health Nutr. 24, 309\u2013317 (2021).","journal-title":"Publ. Health Nutr."},{"key":"8940_CR25","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.tpb.2013.11.006","volume":"92","author":"R Brinks","year":"2014","unstructured":"Brinks, R. & Landwehr, S. Age- and time-dependent model of the prevalence of non-communicable diseases and application to dementia in Germany. Theor. Popul. Biol. 92, 62\u201368 (2014).","journal-title":"Theor. Popul. Biol."},{"key":"8940_CR26","unstructured":"Table 17-10-0057-01 Projected Population, by Projection Scenario, Age and Sex, as of July 1 (x 1,000) (Statistics Canada, 2022); www150.statcan.gc.ca\/t1\/tbl1\/en\/tv.action?pid=1710005701."},{"key":"8940_CR27","unstructured":"Population Projection (FRDK123) (Statbank Denmark, 2023); extranet.dst.dk\/pyramide\/pyramide.htm#!&l=en."},{"key":"8940_CR28","unstructured":"2018-Based Principal Population Projections For 2018-2043, By Sex, NHS Board Area and Single Year of Age (National Records of Scotland, 2020); www.nrscotland.gov.uk\/statistics-and-data\/statistics\/statistics-by-theme\/population\/population-projections\/sub-national-population-projections\/2018-based\/detailed-datasets."},{"key":"8940_CR29","unstructured":"Cheney, W. & Kincaid, D. Numerical Mathematics and Computing 5th edn, 633 (Brooks\/Cole-Thompson, 2004)."},{"key":"8940_CR30","doi-asserted-by":"crossref","unstructured":"Lopes, E. W. et al. Lifestyle factors for the prevention of inflammatory bowel disease. Gut 72, 1093\u20131100 (2023).","DOI":"10.1136\/gutjnl-2022-328174"},{"key":"8940_CR31","doi-asserted-by":"crossref","unstructured":"Burisch, J., Claytor, J., Hernandez, I., Hou, J. K. & Kaplan, G. G. The cost of IBD care\u2014how to make it sustainable. Clin. Gastroenterol. Hepatol. 23, 386\u2013395 (2024).","DOI":"10.1016\/j.cgh.2024.06.049"},{"key":"8940_CR32","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1016\/j.cgh.2020.01.028","volume":"18","author":"AN Ananthakrishnan","year":"2020","unstructured":"Ananthakrishnan, A. N., Kaplan, G. G. & Ng, S. C. Changing global epidemiology of inflammatory bowel diseases: sustaining health care delivery into the 21st century. Clin. Gastroenterol. Hepatol. 18, 1252\u20131260 (2020).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"8940_CR33","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/s12874-023-01944-2","volume":"23","author":"JWY Mak","year":"2023","unstructured":"Mak, J. W. Y. et al. Development of the global inflammatory bowel disease visualization of epidemiology studies in the 21(st) century (GIVES-21). BMC Med. Res. Methodol. 23, 129 (2023).","journal-title":"BMC Med. Res. Methodol."},{"key":"8940_CR34","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1007\/s00535-019-01603-8","volume":"54","author":"Y Murakami","year":"2019","unstructured":"Murakami, Y. et al. Estimated prevalence of ulcerative colitis and Crohn\u2019s disease in Japan in 2014: an analysis of a nationwide survey. J. Gastroenterol. 54, 1070\u20131077 (2019).","journal-title":"J. Gastroenterol."},{"key":"8940_CR35","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1093\/ecco-jcc\/jjz081","volume":"13","author":"SH Park","year":"2019","unstructured":"Park, S. H. et al. A 30-year trend analysis in the epidemiology of inflammatory bowel disease in the Songpa-Kangdong district of Seoul, Korea in 1986-2015. J. Crohns Colitis 13, 1410\u20131417 (2019).","journal-title":"J. Crohns Colitis"},{"key":"8940_CR36","doi-asserted-by":"publisher","first-page":"900251","DOI":"10.3389\/fmed.2022.900251","volume":"9","author":"H Yang","year":"2022","unstructured":"Yang, H., Zhou, R., Bai, X., Guo, M., Ruan, G., Wang, L. & Qian, J. Trend and geographic variation in incidence and prevalence of inflammatory bowel disease in regions across China: a nationwide employee study between 2013 and 2016. Front. Med. 9, 900251 (2022).","journal-title":"Front. Med."},{"key":"8940_CR37","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-019-6858-2","volume":"19","author":"NM Mokhtar","year":"2019","unstructured":"Mokhtar, N. M. et al. A four-decade analysis of the incidence trends, sociodemographic and clinical characteristics of inflammatory bowel disease patients at single tertiary centre, Kuala Lumpur, Malaysia. BMC Publ. Health 19, 550 (2019).","journal-title":"BMC Publ. Health"},{"key":"8940_CR38","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1111\/apt.15178","volume":"49","author":"SC Shah","year":"2019","unstructured":"Shah, S. C. et al. Sex-based differences in the incidence of inflammatory bowel diseases-pooled analysis of population-based studies from the Asia-Pacific region. Aliment Pharmacol. Ther. 49, 904\u2013911 (2019).","journal-title":"Aliment Pharmacol. Ther."},{"key":"8940_CR39","doi-asserted-by":"publisher","first-page":"S16","DOI":"10.1093\/jcag\/gwad009","volume":"6","author":"ME Kuenzig","year":"2023","unstructured":"Kuenzig, M. E. et al. The 2023 impact of inflammatory bowel disease in Canada: indirect (individual and societal) and direct out-of-pocket costs. J. Can. Assoc. Gastroenterol. 6, S16\u2013S22 (2023).","journal-title":"J. Can. Assoc. Gastroenterol."},{"key":"8940_CR40","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1053\/j.gastro.2024.02.016","volume":"166","author":"M Herauf","year":"2024","unstructured":"Herauf, M. et al. Commentary on the epidemiology of inflammatory bowel disease in compounding prevalence nations: toward sustaining healthcare delivery. Gastroenterology 166, 949\u2013956 (2024).","journal-title":"Gastroenterology"},{"key":"8940_CR41","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1097\/01.MIB.0000435441.30107.8b","volume":"20","author":"MD Long","year":"2014","unstructured":"Long, M. D. et al. Challenges in designing a national surveillance program for inflammatory bowel disease in the United States. Inflamm. Bowel Dis. 20, 398\u2013415 (2014).","journal-title":"Inflamm. Bowel Dis."},{"key":"8940_CR42","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1002\/ibd.21511","volume":"17","author":"NA Molodecky","year":"2011","unstructured":"Molodecky, N. A. et al. Challenges associated with identifying the environmental determinants of the inflammatory bowel diseases. Inflamm. Bowel Dis. 17, 1792\u20131799 (2011).","journal-title":"Inflamm. Bowel Dis."},{"key":"8940_CR43","doi-asserted-by":"publisher","first-page":"S45","DOI":"10.1093\/jcag\/gwad013","volume":"6","author":"SR Shaffer","year":"2023","unstructured":"Shaffer, S. R. et al. The 2023 impact of inflammatory bowel disease in Canada: special populations-IBD in seniors. J. Can. Assoc. Gastroenterol. 6, S45\u2013S54 (2023).","journal-title":"J. Can. Assoc. Gastroenterol."},{"key":"8940_CR44","doi-asserted-by":"publisher","first-page":"S111","DOI":"10.1093\/jcag\/gwad007","volume":"6","author":"H Mathias","year":"2023","unstructured":"Mathias, H. et al. The 2023 impact of inflammatory bowel disease in Canada: access to and models of care. J. Can. Assoc. Gastroenterol. 6, S111\u2013S121 (2023).","journal-title":"J. Can. Assoc. Gastroenterol."},{"key":"8940_CR45","doi-asserted-by":"publisher","unstructured":"Chhibba, T. et al. Environmental risk factors of inflammatory bowel disease: towards a strategy of preventative health. J. Crohns Colitis https:\/\/doi.org\/10.1093\/ecco-jcc\/jjaf042 (2025).","DOI":"10.1093\/ecco-jcc\/jjaf042"},{"key":"8940_CR46","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1053\/j.gastro.2023.05.032","volume":"165","author":"JA Raygoza Garay","year":"2023","unstructured":"Raygoza Garay, J. A. et al. Gut microbiome composition is associated with future onset of Crohn\u2019s disease in healthy first-degree relatives. Gastroenterology 165, 670\u2013681 (2023).","journal-title":"Gastroenterology"},{"key":"8940_CR47","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1053\/j.gastro.2020.03.007","volume":"159","author":"J Torres","year":"2020","unstructured":"Torres, J. et al. Serum biomarkers identify patients who will develop inflammatory bowel diseases up to 5 years before diagnosis. Gastroenterology 159, 96\u2013104 (2020).","journal-title":"Gastroenterology"},{"key":"8940_CR48","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1053\/j.gastro.2022.12.042","volume":"164","author":"AE Livanos","year":"2023","unstructured":"Livanos, A. E. et al. Anti-integrin \u03b1v\u03b26 autoantibodies are a novel biomarker that antedate ulcerative colitis. Gastroenterology 164, 619\u2013629 (2023).","journal-title":"Gastroenterology"},{"key":"8940_CR49","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1056\/NEJMoa1902226","volume":"381","author":"KC Herold","year":"2019","unstructured":"Herold, K. C. et al. An anti-CD3 antibody, teplizumab, in relatives at risk for type 1 diabetes. N. Engl. J. Med. 381, 603\u2013613 (2019).","journal-title":"N. Engl. J. Med."},{"key":"8940_CR50","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1016\/S0140-6736(23)02649-1","volume":"403","author":"AP Cope","year":"2024","unstructured":"Cope, A. P. et al. Abatacept in individuals at high risk of rheumatoid arthritis (APIPPRA): a randomised, double-blind, multicentre, parallel, placebo-controlled, phase 2b clinical trial. Lancet 403, 838\u2013849 (2024).","journal-title":"Lancet"},{"key":"8940_CR51","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page, M. J. et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Brit. Med. J. 372, n71 (2021).","journal-title":"Brit. Med. J."},{"key":"8940_CR52","unstructured":"Google Translate (Google, 2022); translate.google.com."},{"key":"8940_CR53","unstructured":"Table 17-10-0005-01 Population Estimates on July 1st, By Age and Sex (Statistics Canada, 2021); www150.statcan.gc.ca\/t1\/tbl1\/en\/cv.action?pid=1710000501."},{"key":"8940_CR54","unstructured":"Maddison Style Estimates of the Evolution of the World Economy: A New 2020 Update (Maddison Project Database, 2020); www.rug.nl\/ggdc\/historicaldevelopment\/maddison\/releases\/maddison-project-database-2020?lang=en."},{"key":"8940_CR55","unstructured":"Population estimates for UK, England and Wales, Scotland and Northern Ireland: mid-2020-april-2021-geography (Office for National Statistics, 2022); www.ons.gov.uk\/datasets\/mid-year-pop-est\/editions\/mid-2020-april-2021-geography\/versions\/1."},{"key":"8940_CR56","unstructured":"FOLK1A: Population at the First Day of the Quarter by Region, Sex, Age and Marital Status (Statistics Denmark, 2022); www.statbank.dk\/statbank5a\/selectvarval\/define.asp?PLanguage=1&subword=tabsel&MainTable=FOLK1A&PXSId=199113&tablestyle=&ST=SD&buttons=0."},{"key":"8940_CR57","unstructured":"Population by Region, Marital Status, Age and Sex: Year 1968\u20132021 (Statistics Sweden, 2022); www.statistikdatabasen.scb.se\/pxweb\/en\/ssd\/START__BE__BE0101__BE0101A\/BefolkningNy\/."},{"key":"8940_CR58","unstructured":"Brazilian Institute of Geography and Statistics. Cidades (2022); cidades.ibge.gov.br\/brasil\/panorama."},{"key":"8940_CR59","unstructured":"World Population Prospects 2019: Data Portal (United Nations Department of Economic and Social Affairs\u2014Population Division, 2019); population.un.org\/dataportal\/home."},{"key":"8940_CR60","unstructured":"Estimates of Resident Population Change and Rankings for Counties in Minnesota (United States Census Bureau, 2022); www2.census.gov\/programs-surveys\/popest\/tables\/."},{"key":"8940_CR61","unstructured":"Number of Inhabitants: Minnesota (United States Census Bureau, 1952); www2.census.gov\/library\/publications\/decennial\/1950\/population-volume-1\/vol-01-26.pdf."},{"key":"8940_CR62","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1097\/XEB.0000000000000054","volume":"13","author":"Z Munn","year":"2015","unstructured":"Munn, Z., Moola, S., Lisy, K., Riitano, D. & Tufanaru, C. Methodological guidance for systematic reviews of observational epidemiological studies reporting prevalence and cumulative incidence data. Int. J. Evid. Based Healthc. 13, 147\u2013153 (2015).","journal-title":"Int. J. Evid. Based Healthc."},{"key":"8940_CR63","unstructured":"OriginPro v.b9.5.5.409 (OriginLab, 2018)."},{"key":"8940_CR64","doi-asserted-by":"crossref","unstructured":"Lajeunesse, M. J. juicr: automated and manual extraction of numerical data from scientific images v.0.1 (2021).","DOI":"10.32614\/CRAN.package.juicr"},{"key":"8940_CR65","unstructured":"R: a language and environment for statistical computing v.4.2.2 (R Foundation for Statistical Computing, 2022)."},{"key":"8940_CR66","first-page":"18","volume":"2","author":"A Liaw","year":"2002","unstructured":"Liaw, A. & Wiener, M. Classification and regression by randomForest. R News 2, 18\u201322 (2002).","journal-title":"R News"},{"key":"8940_CR67","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10462-009-9124-7","volume":"33","author":"L Rokach","year":"2010","unstructured":"Rokach, L. Ensemble-based classifiers. Artific. Intel. Rev. 33, 1\u201339 (2010).","journal-title":"Artific. Intel. Rev."},{"key":"8940_CR68","unstructured":"Lenth, R. V. et al. emmeans: estimated marginal means, aka Least-Squares Means v.1.10.3."},{"key":"8940_CR69","unstructured":"Global Health Observatory. Prevalence of Obesity Among Adults, BMI \u2265 30, Age-Standardized Estimates by Country (World Health Organization, 2017); apps.who.int\/gho\/data\/node.main.A900A?lang=en."},{"key":"8940_CR70","unstructured":"National Records of Scotland. Mid-year Population Estimates: Time Series Data (National Records of Scotland, 2022); www.nrscotland.gov.uk\/statistics-and-data\/statistics\/statistics-by-theme\/population\/population-estimates\/mid-year-population-estimates\/population-estimates-time-series-data."},{"key":"8940_CR71","doi-asserted-by":"publisher","first-page":"920947","DOI":"10.3389\/fcell.2022.920947","volume":"10","author":"GM Morotz","year":"2022","unstructured":"Morotz, G. M. et al. The PTPIP51 coiled-coil domain is important in VAPB binding, formation of ER-mitochondria contacts and IP3 receptor delivery of Ca2+ to mitochondria. Front. Cell Dev. Biol. 10, 920947 (2022).","journal-title":"Front. Cell Dev. Biol."},{"key":"8940_CR72","unstructured":"Mathematica v.13.1 (Wolfram Research, 2022)."},{"key":"8940_CR73","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1093\/ecco-jcc\/jjac138","volume":"17","author":"ML Dorn-Rasmussen","year":"2023","unstructured":"Dorn-Rasmussen, M. L. et al. The incidence and prevalence of paediatric- and adult-onset inflammatory bowel disease in Denmark during a 37-year period\u2014a nationwide cohort study (1980\u20132017). J. Crohns Colitis 17, 259\u2013268 (2023).","journal-title":"J. Crohns Colitis"},{"key":"8940_CR74","unstructured":"Population 1. January (FOLK2) (Statbank Denmark, 2023); extranet.dst.dk\/pyramide\/pyramide.htm#!&l=en."},{"key":"8940_CR75","first-page":"425","volume":"32","author":"R Brinks","year":"2015","unstructured":"Brinks, R. & Landwehr, S. A new relation between prevalence and incidence of a chronic disease. Math. Med. Biol. 32, 425\u2013435 (2015).","journal-title":"Math. Med. Biol."},{"key":"8940_CR76","doi-asserted-by":"publisher","first-page":"371","DOI":"10.2307\/2983150","volume":"154","author":"N Keiding","year":"1991","unstructured":"Keiding, N. Age-specific incidence and prevalence: a statistical perspective. J. R. Stat. Soc. 154, 371\u2013412 (1991).","journal-title":"J. R. Stat. Soc."},{"key":"8940_CR77","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1111\/dme.13902","volume":"36","author":"T T\u00f6nnies","year":"2019","unstructured":"T\u00f6nnies, T. et al. Projected number of people with diagnosed Type 2 diabetes in Germany in 2040. Diabet. Med. 36, 1217\u20131225 (2019).","journal-title":"Diabet. Med."},{"key":"8940_CR78","doi-asserted-by":"publisher","first-page":"e0264739","DOI":"10.1371\/journal.pone.0264739","volume":"17","author":"D Voeltz","year":"2022","unstructured":"Voeltz, D., T\u00f6nnies, T., Brinks, R. & Hoyer, A. Future prevalence of type 2 diabetes\u2014a comparative analysis of chronic disease projection methods. PLoS ONE 17, e0264739 (2022).","journal-title":"PLoS ONE"},{"key":"8940_CR79","doi-asserted-by":"publisher","first-page":"E1394","DOI":"10.1503\/cmaj.190976","volume":"192","author":"ME Kuenzig","year":"2020","unstructured":"Kuenzig, M. E., Manuel, D. G., Donelle, J. & Benchimol, E. I. Life expectancy and health-adjusted life expectancy in people with inflammatory bowel disease. Can. Med. Assoc. J. 192, E1394\u2013E1402 (2020).","journal-title":"Can. Med. Assoc. J."},{"key":"8940_CR80","unstructured":"Table 17-10-0040-01 Estimates of the Components of International Migration, Quarterly (Statistics Canada, 2023); www150.statcan.gc.ca\/t1\/tbl1\/en\/tv.action?pid=1710004001."},{"key":"8940_CR81","unstructured":"Immigration and emigration (Statbank Denmark, 2023); www.dst.dk\/en\/Statistik\/emner\/borgere\/flytninger\/ind-og-udvandring."},{"key":"8940_CR82","unstructured":"Total Migration To or From Scotland (National Records of Scotland, 2023); www.nrscotland.gov.uk\/statistics-and-data\/statistics\/statistics-by-theme\/migration\/migration-statistics\/migration-flows\/total-migration-to-or-from-scotland."},{"key":"8940_CR83","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1038\/ajg.2015.52","volume":"110","author":"EI Benchimol","year":"2015","unstructured":"Benchimol, E. I. et al. Inflammatory bowel disease in immigrants to Canada and their children: a population-based cohort study. Am. J. Gastroenterol. 110, 553\u2013563 (2015).","journal-title":"Am. J. Gastroenterol."},{"key":"8940_CR84","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1136\/gutjnl-2020-321798","volume":"70","author":"M Agrawal","year":"2021","unstructured":"Agrawal, M. et al. Inflammatory bowel diseases among first-generation and second-generation immigrants in Denmark: a population-based cohort study. Gut 70, 1037\u20131043 (2021).","journal-title":"Gut"},{"key":"8940_CR85","doi-asserted-by":"crossref","unstructured":"Polyanin, A. D., Zaitsev, V. F. & Moussiaux, A. Handbook of First Order Partial Differential Equations Vol. 1 (Taylor & Francis, 2002).","DOI":"10.1201\/b16828"},{"key":"8940_CR86","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1136\/gutjnl-2013-304636","volume":"63","author":"J Burisch","year":"2014","unstructured":"Burisch, J. et al. East\u2013west gradient in the incidence of inflammatory bowel disease in Europe: the ECCO-EpiCom inception cohort. Gut 63, 588\u2013597 (2014).","journal-title":"Gut"},{"key":"8940_CR87","doi-asserted-by":"publisher","unstructured":"Hracs, L. et al. Data for \u2018Global evolution of inflammatory bowel disease across epidemiological stages\u2019. Figshare https:\/\/doi.org\/10.6084\/m9.figshare.24952557 (2025).","DOI":"10.6084\/m9.figshare.24952557"}],"container-title":["Nature"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41586-025-08940-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41586-025-08940-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41586-025-08940-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T15:05:29Z","timestamp":1749654329000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41586-025-08940-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,30]]},"references-count":87,"journal-issue":{"issue":"8067","published-print":{"date-parts":[[2025,6,12]]}},"alternative-id":["8940"],"URL":"https:\/\/doi.org\/10.1038\/s41586-025-08940-0","relation":{},"ISSN":["0028-0836","1476-4687"],"issn-type":[{"value":"0028-0836","type":"print"},{"value":"1476-4687","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,30]]},"assertion":[{"value":"8 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.T.A. has received research funding from the National Institute of Health, Department of Defense, The Leona M. and Harry B. Helmsley Charitable Trust (through the University of Miami), Crohn\u2019s and Colitis Foundation and Kenneth Rainin Foundation; she is a consultant or served on advisory boards for AbbVie, Arena Pharmaceuticals (now Pfizer), Bristol Myers Squibb, Celsius Therapeutics, Eli Lilly and Company, Gilead Sciences, Janssen Pharmaceuticals, Janssen Global Services, Pfizer Pharmaceutical, Prometheus Biosciences, UCB Biopharma; she has received fees for lecturing from Alimentiv, Janssen Pharmaceuticals, Prime CME and WebMD Global LLC. D.B. has received speaking fees from AbbVie, Takeda and Janssen, and consulting fees from AbbVie, Takeda, Janssen and Amgen. R.B. has received grants\/research support from the Asian Healthcare Foundation, Pfizer Global, Indian council of Medical Research (ICMR) and the Leona M and Harry B Helmsley Charitable Trust; and advisory board fees from Abbott, AstraZeneca, Cadila, Cipla, Celltrion, Dr Reddy Labs, Emcure, Ferring Pharmaceuticals, Hetero Drugs, Janssen, La Renon, MSN Labs, Mankind Pharma, Menarini, Micro Labs, Nestle, Pfizer, RPG Lifesciences, Sun Pharmaceuticals, Systopic, Takeda Pharmaceuticals, Torrent, Waterley and Zydus. E.I.B. has acted as a consultant for McKesson Canada and the Dairy Farmers of Ontario for matters unrelated to medications used to treat IBD; he has also acted as a consultant for the Canadian Agency for Drugs and Technology in Health (CADTH). C.N.B. is supported by the Bingham Chair in Gastroenterology; has served on advisory boards for AbbVie Canada, Amgen Canada, Bristol Myers Squibb Canada, Eli Lilly Canada, JAMP Pharmaceuticals, Janssen Canada, Pendopharm Canada, Sandoz Canada, Takeda Canada and Pfizer Canada; Consultant for Takeda; Educational grants from AbbVie Canada, Bristol Myers Squibb Canada, Ferring Canada, Pfizer Canada, Takeda Canada, Janssen Canada, Organon Canada, Eli Lilly Canada and Amgen Canada; speaker\u2019s panel for AbbVie Canada, Janssen Canada, Pfizer Canada and Takeda Canada. Received research funding from AbbVie Canada, Amgen Canada, Sandoz Canada, Takeda Canada and Pfizer Canada. E.B.-M. has served as a speaker and consultant for Janssen, Chiesi, Takeda and Kern. J.B. reports grants and personal fees from AbbVie, grants and personal fees from Janssen-Cilag, personal fees from Celgene, grants and personal fees from MSD, personal fees from Pfizer, grants and personal fees from Takeda, grants and personal fees from Tillots Pharma, personal fees from Samsung Bioepis, grants and personal fees from Bristol Myers Squibb, grants from Novo Nordisk, personal fees from Pharmacosmos, personal fees from Ferring and personal fees from Galapagos; outside the submitted work. I.D. received consultation fees\/served in advisory boards\/speakers\u2019 bureaus for AbbVie, Athos, Arena, Celltrion, Celgene\/BMS, Eli-Lilly, Ferring, Food Industries Organization, Gilead, Galapagos, Iterative Scopes, Janssen, Neopharm, Pfizer, Roche\/Genentech, Sangamo, Sublimity, Sandoz, Takeda, Wildbio and Prometheus. Jill Roberts IBD Center, shareholder: Gutreat, Harp diagnostics. S.E.O. has received honoraria for speaking from AbbVie and Janssen. A. Forss has served as a speaker and advisory board member for Janssen and Tillotts Pharma. R.G. has received research funding from AbbVie, Janssen, Zespri, Comvita, Goodman Fielder and Takeda; he has served on advisory boards for AbbVie, Janssen, Zespri, Comvita and Takeda; and has received honoraria from AbbVie, Janssen, Zespri and Takeda. J.L.H. has received consultation and speaking fee from Janssen, Ferring, AbbVie and Takeda. I.H. has received consulting and speaking honoraria from AbbVie, Janssen, Ferring, LF Asia, Pfizer and Takeda. B.I. has been member of advisory boards for AbbVie, Janssen and Takeda. G.-R.J. is funded by a Wellcome Trust Clinical Research Career Development Fellowship and has received speaker fees from AbbVie, Ferring Pharmaceuticals, Janssen, Takeda, Fresenius Kabi and Pfizer. F.J.-B. has received consulting and speaking fees from AbbVie, Janssen, Pfizer, Celltrion and Takeda. J.K. has served on advisory boards for Janssen Kazakhstan and has been a consultant for Takeda and Ferring; has been on speaker panels for Janssen, Takeda, Ferring, Thermo Fisher Scientific; and has received research funding from Ferring Kazakhstan. G.G.K. has received honoraria for speaking or consultancy from AbbVie, Amgen, Janssen, Pfizer, Sandoz and Pendophram; received grants for research from Ferring and for educational activities from AbbVie, Bristol Myers Squibb, Ferring, Fresenius-Kabi, Janssen, Pfizer, Takeda; he shares ownership of a patent: Treatment of inflammatory disorders, autoimmune disease and PBC; UTI Limited Partnership, assignee; patent WO2019046959A1, PCT\/CA2018\/051098; 7 September 2018. T.K. has served as an advisory board member, consultant or speaker for AbbVie, Activaid, Ajinomoto Bio-Pharma, Alfresa Pharma, Alimentiv, Astellas Pharma, Bristol Myers Squibb, Celltrion, Covidien, EA Pharma, Eisai, Eli Lilly, Ferring Pharmaceuticals, Gilead Sciences, Janssen Pharmaceuticals, JIMRO, JMDC, Kissei Pharmaceutical, Kyorin Pharmaceutical, Mitsubishi Tanabe Pharma, Mochida Pharmaceutical, Nippon Kayaku, Pfizer, Takeda, Thermo Fisher Scientific and Zeria Pharmaceutical, and has received research funding from AbbVie, Alfresa Pharma, EA Pharma, Kyorin Pharmaceutical, Mochida Pharmaceutical, Nippon Kayaku, Otsuka Holdings, Sekisui Medical, Takeda, Thermo Fisher Scientific and Zeria Pharmaceutical. P.G.K. has received consulting and speaking honorarium from AbbVie, Janssen, Pfizer and Takeda. He also has received scientific grants from Pfizer and Takeda. P.L.L. has been a speaker and\/or advisory board member for AbbVie, Amgen, BioJamp, Bristol Myers Squibb, Fresenius Kabi, Genetech, Gilead, Janssen, Merck, Mylan, Organon, Pendopharm, Pfizer, Roche, Sandoz, Takeda, Tillots and Viatris; and has received unrestricted research grants from AbbVie, Gilead, Takeda and Pfizer. C.W.L. is funded by a UK Research and Innovation Future Leaders Fellowship and has acted as a speaker and\/or consultant to AbbVie, Janssen, Takeda, Pfizer, Galapagos, GSK, Gilead, Vifor Pharma, Ferring, Dr Falk, BMS, Boehringer Ingelheim, Novartis, Sandoz, Celltrion, Cellgene, Amgen, Samsung Bioepis, Fresenius Kabi, Tillotts, Trellus Health and Iterative Health. B.L. has received speaking fees from Tillotts Pharma and Janssen Cilag; consultancy fees from Tillotts Pharma and Bristol Myers Squib; and has received unrestricted research grants from Janssen Cilag, Tillotts Pharma; outside the submitted work. E.V.L. has consulted for AbbVie, Alvotech, Amgen, Arena, Astellas, Avalo, Boehringer Ingelheim, Bristol-Myers Squibb, Celltrion, Eli Lilly, Fresenius Kabi, Genentech, Gilead, GlaxoSmithKline, Gossamer Bio, Iota Biosciences, Iterative Health, Janssen, Morphic, Ono, Protagonist, Sun, Surrozen, Takeda, TR1X and UCB; has received research support from AbbVie, AstraZeneca, Bristol-Myers Squibb, Celgene\/Receptos, Genentech, Gilead, Gossamer Bio, Janssen, Takeda, Theravance and UCB; and is a shareowner of Exact Sciences. S.C.N. has served as an advisory board member for Pfizer, Ferring, Janssen and AbbVie and received honoraria as a speaker for Ferring, Tillotts, Menarini, Janssen, AbbVie and Takeda; has received research grants through her affiliated institutions from Olympus, Ferring and AbbVie; is a founder member, non-executive director, non-executive scientific advisor and shareholder of GenieBiome Ltd; and receives patent royalties through her affiliated institutions. S.O. has received speaking fees from Mitsubishi Tanabe Pharma and consulting fees from EA Pharma. O.O. has been PI on projects at Karolinska Institutet partly financed by investigator-initiated grants from Janssen, Takeda, AbbVie, Pfizer, Bristoll Myers Squibb and Ferring, and also report grants from Pfizer, AbbVie, Janssen and Galapagos in the context of a national safety monitoring programs; none of these studies have any relation to the present study. The Karolinska Institutet has received fees for lectures and participation on advisory boards by O.O. from Janssen, Ferring, Takeda and Pfizer on topics not related to the present study. R.P. has received consulting fees from Abbott, AbbVie, Alimentiv (formerly Robarts), Amgen, Arena Pharmaceuticals, AstraZeneca, Biogen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Celltrion, Cosmos Pharmaceuticals, Eisai, Elan, Eli Lilly, Ferring, Galapagos, Fresenius Kabi, Genentech, Gilead Sciences, Glaxo-Smith Kline, JAMP Bio, Janssen, Merck, Mylan, Novartis, Oppilan Pharma, Organon, Pandion Pharma, Pendopharm, Pfizer, Progenity, Protagonist Therapeutics, Roche, Sandoz, Satisfai Health, Shire, Sublimity Therapeutics and Takeda. A.B.Q. has received speaking honorarium from AbbVie, Apsen and Janssen. R.A.R.A. has received speaking and consulting honoraria from AbbVie, Astra Zeneca, Ferring, Pfizer, Janssen and Takeda. D.T.R. has received grant support from Takeda; and has served as a consultant for AbbVie, Altrubio, Abivax SA, Altrubio, Avalo Therapeutics, Bausch Health, Bristol-Myers Squibb, Buhlmann Diagnostics, ClostraBio, Connect BioPharma, Douglas Pharmaceuticals, Eli Lilly, Genentech, InDex Pharmaceuticals, Iterative Health, Janssen Pharmaceuticals, Odyssey Therapeutics, Pfizer, Sanofi and Takeda Pharmaceuticals; he serves on the board of trustees for the Crohn\u2019s & Colitis Foundation and is on the board of directors for Cornerstones Health. H.S. has received honoraria for speaking from Astellas, AbbVie, Biofermin, EA Pharma, Janssen, Kissei, Miyarisan, Otsuka, Tanabe-Mitsubishi, Takeda, Tsumura and Viatris; and received grants for research from Toh-so and Biofermin. M.T. has received consulting and speaking fees from AbbVie, Janssen and Takeda. D.T. received consultation fees, research grants, royalties or honoraria from Janssen, Pfizer, Shaare Zedek Medical Center, Hospital for Sick Children, Ferring, AbbVie, Takeda, Prometheus Biosciences, Lilly, Roche, Thermo Fisher Scientific, BMS and SorrisoPharma. S.C.W. has received consultancy fees from AbbVie, Bristol-Myers Squibb, Celltrion, Ferring Pharmaceuticals, Janssen, Pfizer, Takeda and Tanabe, and speaker fees from AbbVie, Bristol-Myers Squibb, Celltrion, Excelsior Biopharma, Ferring Pharmaceuticals, Pfizer, Janssen, Sanofi, Takeda and Tanabe. T.W. received funding for educational activities from AbbVie and Pfizer. J.K.Y.-F. is a speaker bureau member for AbbVie, Alfasigma, Asofarma, Bristol Myers Squibb, Carnot, Celltrion, Chinoin, Farmasa, Ferring, Janssen, Siegfried Rhein and Takeda; is a clinical research investigator Bristol Myers Squibb and Takeda; has been member of advisory boards for AbbVie, Celltrion, Ferring, Janssen and Takeda; has received research grants from Takeda; received payments for lectures from AbbVie, Alfasigma, Asofarma, Bristol Myers Squibb, Carnot, Celltrion, Chinoin, Farmasa, Ferring, Janssen, Siegfried Rhein and Takeda; and is an advisory board member of the AbbVie, Celltrion, Ferring, Janssen and Takeda. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}